247 related articles for article (PubMed ID: 37537301)
1. CD8
Lerner EC; Woroniecka KI; D'Anniballe VM; Wilkinson DS; Mohan AA; Lorrey SJ; Waibl-Polania J; Wachsmuth LP; Miggelbrink AM; Jackson JD; Cui X; Raj JA; Tomaszewski WH; Cook SL; Sampson JH; Patel AP; Khasraw M; Gunn MD; Fecci PE
Nat Cancer; 2023 Sep; 4(9):1258-1272. PubMed ID: 37537301
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
3. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
Stojanovic A; Correia MP; Cerwenka A
Front Immunol; 2018; 9():827. PubMed ID: 29740438
[TBL] [Abstract][Full Text] [Related]
4. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
Kim Y; Born C; Bléry M; Steinle A
Front Immunol; 2020; 11():960. PubMed ID: 32582150
[TBL] [Abstract][Full Text] [Related]
5. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
[TBL] [Abstract][Full Text] [Related]
6. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
Cerboni C; Ardolino M; Santoni A; Zingoni A
Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
[TBL] [Abstract][Full Text] [Related]
7. Stress Signal ULBP4, an NKG2D Ligand, Is Upregulated in Multiple Sclerosis and Shapes CD8
Carmena Moratalla A; Carpentier Solorio Y; Lemaitre F; Farzam-Kia N; Levert A; Zandee SEJ; Lahav B; Guimond JV; Haddad E; Girard M; Duquette P; Larochelle C; Prat A; Arbour N
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34873031
[TBL] [Abstract][Full Text] [Related]
8. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
10. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
11. The effect of photodynamic therapy on tumor cell expression of major histocompatibility complex (MHC) class I and MHC class I-related molecules.
Belicha-Villanueva A; Riddell J; Bangia N; Gollnick SO
Lasers Surg Med; 2012 Jan; 44(1):60-8. PubMed ID: 22246985
[TBL] [Abstract][Full Text] [Related]
12. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
Lazarova M; Wels WS; Steinle A
Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
[TBL] [Abstract][Full Text] [Related]
13. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
[TBL] [Abstract][Full Text] [Related]
14. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.
Lundholm M; Schröder M; Nagaeva O; Baranov V; Widmark A; Mincheva-Nilsson L; Wikström P
PLoS One; 2014; 9(9):e108925. PubMed ID: 25268476
[TBL] [Abstract][Full Text] [Related]
15. A dual function of NKG2D ligands in NK-cell activation.
Cheney EE; Wise EL; Bui JD; Schreiber RD; Carayannopoulos LN; Spitzer D; Zafirova B; Polic B; Shaw AS; Markiewicz MA
Eur J Immunol; 2012 Sep; 42(9):2452-8. PubMed ID: 22740149
[TBL] [Abstract][Full Text] [Related]
16. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
[TBL] [Abstract][Full Text] [Related]
17. Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown.
Trichet V; Benezech C; Dousset C; Gesnel MC; Bonneville M; Breathnach R
J Immunol; 2006 Nov; 177(9):6129-36. PubMed ID: 17056540
[TBL] [Abstract][Full Text] [Related]
18. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
19. Induction of NKG2D ligand expression on tumor cells by CD8
Hu J; Xia X; Gorlick R; Li S
Oncogene; 2019 Dec; 38(49):7433-7446. PubMed ID: 31427736
[TBL] [Abstract][Full Text] [Related]
20. Recruiting T cells and sensitizing tumors to NKG2D immune surveillance for robust antitumor immune response.
Li X; Guo X; Huang J; Lin Q; Qin B; Jiang M; Shan X; Luo Z; Zhang J; Shi Y; Lu Y; Liu X; Du Y; Yang F; Luo L; You J
J Control Release; 2023 Jan; 353():943-955. PubMed ID: 36535542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
